Our Business Plan sets out our priorities for the business year 2023 to 2024.
Last month we held three more sector focused forums. Meeting together in this way has many benefits, as some of the things we talked about can illustrate.
We recently started a new programme of sector-focused stakeholder engagement forums starting with leaders from the Human Application, ODT, Anatomy and Post Mortem sectors, where the Terms of Reference were agreed. We’re looking forward to further forums later in the year.
The forums have three functions:
to provide a forum to discuss sector-focused regulatory issues
to consider regulatory policies and practice
to share relevant regulatory concerns, knowledge, insight, and intelligence.
Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended) licensing standards.
We’ve published new inspection reports from establishments in research, human application, anatomy, and post-mortem sectors.
We’ve published 6 new inspection reports from establishments in human application, research, and post-mortem sectors.
On inspections we look at compliance with HTA standards including consent, governance and quality systems, traceability, and premises, facilities and equipment. We check whether there are any minor, major or critical shortfalls against these standards.
Read the latest reports:
Last week we kicked off our new programme of stakeholder events by hosting a roundtable with devolved administrations.
In our last blog, the HTA outlined how we and our stakeholders have a clear role to play in achieving the governments’ Life Sciences Vision, together delivering a progressive UK regulatory offer that unlocks innovation while safeguarding patients and ensuring public confidence. To do this, we need to constructively challenge our regulatory model and tools, looking at how we can continue to improve outcomes for patients and the